We have developed a strategy for the detection, localization and sequence determination of point mutations in the mRNA coding for the a1(l) and «2(l) chains of type I collagen. Point mutations are detected by RNase A cleavage of mismatches in RNA/RNA hybrids. The mRNAs coding for the fibrillar collagens present special problems for hybrid analysis because of their large size and their GC-rich and repetitive sequences. We have generated a series of overlapping antisense riboprobes covering the entire proa1(l) and proa2(l) mRNAs. Uniformly labelled normal antisense riboprobes are hybridized with the total fibroblast RNA of patients with possible mutations in type I collagen. Mismatches in the resulting RNA/RNA hybrids are cleaved with RNase A and the labelled riboprobe cleavage products are examined electrophoretically. The sensitivity and specificity of the system were demonstrated by the detection and localization of a known point mutation in the codon for a1 (I) glycine 988 (1). DNA for sequencing the mutations localized by hybrid analysis may be obtained by either (1) generation of a fibroblast cDNA library and isolation of both alleles by plaque screening, or (2) a more rapid method using first strand cDNA synthesis from poly (A + )-mRNA, followed by PCR amplification of the mutation-containing region of the DNA/RNA hybrid. This strategy for detection and isolation has wide application not only for mutations causing connective tissue disorders, but also for mutations in other large and repetitive genes.
INTRODUCTION
The identification of specific mutations in the genes of individuals with genetic disorders has led to a greater understanding of both disease states and normal gene functions. Mutations which result in either the creation or loss of a restriction endonuclease cleavage site or in the insertion or deletion of a sizable segment of coding sequence have been easily amenable to detection, mapping and sequencing. The location of other mutations, especially single base changes, has often been inferred from analysis of the structure or function of the protein product of the gene. For some mutations, the entire coding region of both alleles of the gene has been sequenced in individual patients when the mutation could not be localized by protein studies. Clearly, this approach to the detection of mutations is limited to smaller genes. A significant advance in the detection of single base substitutions occurred with the development of a method for detecting single base pair mismatches in RNA/DNA duplexes by ribonuclease A (RNase A) cleavage (2) . This enzymatic method was pioneered using a variety of previously characterized mutations in j3-globin DNA. The method was extended to RNA/RNA hybrids by Winter (3) . The introduction of polyuridylic acid affinity paper (mAP) to the procedure (4) provided a general method for the identification of mutations in the coding region of low abundance mRNAs. The feasibility of RNA/RNA hybrids as a screening method for point mutations was demonstrated by probing the mRNA of patients with Lesch-Nyhan syndrome with an antisense riboprobe complementary to the complete hypoxanthine phosphoribosyltransferase (HPRT) mRNA (5) .
The detection of point mutations causing amino acid substitutions in the fibrillar collagens has been limited by dependence on protein studies. Type I collagen is a heterotrimer, composed of two al(I) and one a2(I) chains. The chains associate in the proper proportions at a region in the carboxyl terminal extension and helix formation proceeds toward the amino terminal end. Amino acid substitutions in type I collagen which cause a decrease in the rate of collagen triple helix formation result in increased hydroxylation and glycosylation of lysine and proline residues (6) located amino terminal to the mutation. Thus the mutation can often be localized to a region of the helix by analyzing the gradient of peptide overmodification after cyanogen bromide (CB) cleavage of the collagen chains. However, overmodification does not distinguish between mutations in the a 1(1) or a2(I) chains comprising the helix. Additional point mutations may be detected by isoelectric focusing if a CB peptide contains an amino acid substitution with a charge change (7, 8) . Substitutions of cysteine for glycine may be easily detected and localized when they allow disulfide cross-linking of a 1(1) chains in the triple helix (1, 9, 10) . These protein studies have facilitated the detection of point mutations in the a 1(1) or a2(I) chains of type I collagen of patients with osteogenesis imperfecta (01), a generalized disorder of connective tissue in which bone fragility is the clinical hallmark (11) . However, point mutations which do not result in the alterations of helix structure outlined above will not be detected by protein methodology.
The ability to detect point mutations in the collagen mRNA of patients with connective tissue disorders would provide increased sensitivity and more accurate localization than protein methodology alone. Use of RNA/RNA hybrid analysis of patient mRNA would also avoid the detection of numerous polymorphisms in intronic sequences. However, the fibrillar collagen genes present special problems for the detection of point mutations by this methodology because of the large size of the proa chains and the repetitive and GC-rich nature of their coding regions (12, 13) . We have developed a strategy for the detection, localization and sequence determination of point mutations in the mRNAs coding for the two chains of type I collagen. This strategy utilizes RNase A cleavage of mismatches in RNA/RNA hybrids between patient mRNA and a series of overlapping antisense riboprobes synthesized from the cDNAs of both type I procollagen chains. Although the type I collagen message is abundant in cultured fibroblasts, we have found it necessary to lower background by using poly U affinity paper to isolate RNA/RNA hybrids before RNase digestion. DNA containing mutations localized by RNase A cleavage may be cloned and sequenced in two ways. First, one may generate a cDNA library from the patient's fibroblast mRNA and isolate both alleles by plaque screening. Second, one may use a more rapid method that involves amplification of the mutation-containing region by the polymerase chain reaction (PCR) (14) . This general method for detection and isolation of point mutations has wide application to other large genes with repetitive sequences.
We have utilized this system for the two genes coding for type I collagen and the mRNA of patients with osteogenesis imperfecta. We report here the sensitivity and specificity of the system for a known point mutation in the a 1(1) mRNA of a patient with lethal osteogenesis imperfecta (1). Mismatches have also been detected in OI patients whose mutations were previously unknown. We report a mismatch in the a 1(1) mRNA of a patient with Type IV 01 which was determined to be a polymorphism.
We also report a proband with lethal OI in whose mRNA we have detected a new functional mutation, a point mutation causing a substitution for glycine in the a2(I) chain. We investigated the type I collagen protein and RNA from the cultured fibroblasts of the lethal proband and both parents. We have previously demonstrated that the cultured dermal fibroblasts of the proband synthesize both a normal type I collagen and an overmodified form of type I collagen which is not present in parental or control fibroblast lines (Grange, Lewis and Marini; Am. J. Med. Genet., in press). Here we demonstrate that overmodification extends the entire length of the helical region of type I collagen. A mismatch was detected in the carboxyl-terminal quarter of the proband's a2(I) mRNA; no mismatches were detected in the proband's al(I) mRNA or in either mRNA of the parents. The region surrounding the mismatch was amplified using PCR and the amplified product was subcloned. Normal and mutant alleles were distinguished by RNase A digestion of DNA/RNA hybrids between subclones and the antisense riboprobe originally used to detect the mutation. Sequencing of both alleles in this region identified a single nucleotide change responsible for a substitution of an aspartic acid for glycine residue 805 of the a2(I) chain.
MATERIALS AND METHODS

Generation of P Gem R Clones
Segments of the cDNA for a 1(1) and a2(I) were subcloned into pGem (16) vectors using standard methods. Parent plasmids for each segment and the restriction sites used for subcloning are shown in Table 1 . We are grateful to Drs. Ramirez, Myers and Jaenish for providing the parent cDNA clones. Subclones were oriented so that all antisense probes were generated using the T7 promoter.
Synthesis of Antisense Riboprobes
Antisense riboprobes were synthesized using linearized pGEM subclones, according to the Promega Riboprobe R kit directions. Probes were labelled with a-32 P-CTP and were used for hybrid analysis within 36 hrs of synthesis.
RNA/RNA Hybrid Analysis
Total RNA was isolated from cultured fibroblasts of patient and control cell lines using the acid-phenol method (22) . Approximately 100 ug of total RNA were mixed with about 2 x 10 5 cpm of labelled riboprobe in a hybridization cocktail of 80% formamide, 400 mM NaCl and 40 mM Pipes, pH 6.7, and sealed in a capillary tube. Samples in the capillaries were heated at 85°C for 5 mins, transferred rapidly to a 50°C bath and hybridized overnight. After the NaCl concentration was adjusted to 0.3 M, hybridized samples were applied to mAP membrane (4) (Amersham) and the selected pory(A+)-mRNA was eluted from the membrane according to the methods of Gibbs and Caskey (5) . Samples were digested with RNase A (8 /tg/ml, Sigma, Type X) in 30 mM Tris, pH 7.5, 3 mM EDTA, 200 mM NaCl and 100 mM LiCl for 1 hr at 30°C (2). The reaction was treated with 150 /tg/ml proteinase K in the presence of 0.6% SDS for 15 mins at 37°C. Reaction products were extracted once with phenol/chloroform, once with chloroform and then ethanol precipitated with carrier tRNA. Half of the reaction products was electrophoresed on a 5% PA-7M urea gel and half on an 8% PA-7M urea gel. A P 32 -end-labelled Hae IH digest of 0X-174 was used for size markers.
Isolation and Sequencing of Mutations
Poly (A+)-RNA was purified from total fibroblast RNA using a Pharmacia mRNA spin column according to the manufacturer's directions. An antisense oligonucleotide primer located downstream from the mutation in question was hybridized with 300-500 ng of poly (A+)-RNA in lOmM Pipes, pH 6.4, 400 mM NaCl and 1 mM EDTA (23) . In the case shown in Fig.  4B , an oligonucleotide complementary to nucleotides 3100-3129 was hybridized to the poly(A+)-mRNA; 20 units of avian reverse transcriptase (Boehringer-Manheim) were used for the first strand cDNA synthesis at 42° for two hours. The resulting hybrid was used as a substrate for the polymerase chain reaction (PCR). PCR was done using a 39 mer oligonucleotide, complementary to nucleotides 2102-2131 plus an EcoRI linker, as the upstream primer and a 39-mer, complementary to nucleotides 3055 -3084 plus a Hind HI linker, as the downstream primer. PCR was performed for 40 cycles of 1 min at 94°C, 2 min at 55°C and 3 min at 72°C. The PCR product was digested with Hind m/EcoRI, gel purified and ligated with Hind HI/EcoRI digested pGEM vector. Isolates containing insert were screened by DNA/RNA hybrid analysis to distinguish between clones with normal or mutant alleles. For DNA/RNA hybrids, the labelled antisense riboprobe (HB6) used in the detection of the mismatch in the proband's RNA was hybridized at 50°C with linearized miniprep DNA of isolates from the subcloned PCR material. Because poly-U membrane selection of hybrids was not possible for DNA/RNA hybrids, the hybrids were digested directly with RNase A and then treated as for RNA/RNA hybrids (Fig. 8) .
Both alleles were sequenced for the entire HB6 probe region using the dideoxy chain termination method (24) and the Promega reverse transcriptase system. A 30-mer complementary to nucleotides 2612-2642 of the published a2(I) sequence (21) was used as the primer for the sequence analysis shown (Fig. 9) .
For the case shown in Fig 4A , a 30-mer complementary to nucleotides coding for amino acids 1030-1039 of a 1(1) was used for cDNA synthesis. PCR amplification used a 39-mer complementary to nucleotides coding for amino acids 770-779 as the upstream primer and a 39-mer complementary nucleotides coding for amino acids 1013-1022 as the downstream primer. The primers used for PCR each contained a restriction enzyme linker, Hind III for the downstream oligo and EcoRI for the upstream oligo. Subclones were sequenced (Fig. 5 ) using the dideoxy chain termination method.
Cyanogen bromide peptides
CNBr peptides were prepared from 3 H-labelled collagen of the proband, parental and control cell lines by minor modification of published procedure (25) . The individual a chains were sliced from a 5% polyacrylamide-SDS-urea gel and treated with cyanogen bromide for two hrs. The CNBr peptides were then electrophoresed into a 10% polyacrylamide-SDS-urea gel as previously described (26) .
RESULTS
General Plan for the Detection, Localization and Sequencing of Mutations in the mRNA of Type I Collagen
The strategy we employed in studying the mRNA for the two chains of type I collagen is shown in Figure 1 . Panel A is a diagram of the RNA/RNA hybrid method that was used to screen patient mRNA for mismatches. Panel B outlines our approach to the amplification and sequencing of the region of patient cDNA containing probable point mutations.
The detection of point mutations involved cleavage of mismatches in RNA/RNA hybrids by RNase A (see Materials and Methods for details). This hybrid analysis was done essentially according to the methodology of Gibbs and Caskey (5), in which poly-U membrane was used to separate poly(A+)-mRNA containing the RNA/RNA hybrids from unhybridized probe, tRNA and ribosomal RNA prior to RNase A digestion ( Figure 1A) . Modifications of the methodology were required because of the size and complexity of the fibrillar collagen sequences. For type I collagen, two mRNAs of about 5 kb each require examination, one for each of the two chains, cd(I) and a2(I), composing the heterotrimer. Furthermore, the sequences are GC-rich and highly repetitive. Since the helical The fibroblast poly (A+)-mRNA is isolated from total RNA with an oligo-dT spin column. Using an appropriate oligonucleotide primer located downstream from the putative mutation and avian reverse transcriptase, a DNA/RNA hybrid is generated by first strand cDNA synthesis. This hybrid is used directly as a substrate for polymerase chain reaction. To amplify the region containing the mismatch, oligonucleotide primers for PCR are complementary to regions on either side of the putative mutation and contain a restriction enzyme linker. After amplification, the linkers are digested and the fragments are subcloned into appropriate vectors and sequenced.
region of collagen is composed of repeating units of Gly-X-Y, where gly is glycine, X often proline and Y is often hydroxyproline, every nine base pair unit has a high degree of homology with every other nine base pair unit (13). These extremely repetitive sequences pose theoretical problems for hybrid analysis because there are multiple regions of RNA with high, but not complete, homology to which some fraction of the riboprobe might hybridize. In addition, since target RNA is itself composed of highly repetitive sequences, some regions of probe might be complementary to multiple regions within the target sequences and a fraction of the total probe might hybridize with a variable extent of misalignment, leaving unhybridized loops of nine base pairs scattered along the probe. In both of these situations, cleavage bands from digestion of unhybridized regions of probe might be confused with detection of a significant mismatch. We dealt with the size of the collagen messages by employing a series of overlapping antisense riboprobes to the mRNAs for a 1(1) and a2(I). Probes were limited to approximately 1 kb or less in size so that the RNase A digestion products could be separated from full length probe by gel electrophoresis. To maximize the specificity of hybridization with highly repetitive sequences in both the probe and the target RNA, we chose hybridization temperatures close to the hybrid melting temperature.
Panel B of Figure 1 outlines our approach to isolating and sequencing mutations that have been detected by RNase A digestion of mismatches in RNA/RNA hybrids. An oligonucleotide primer, located downstream from the mismatch detected by digestion of RNA/RNA hybrids, is hybridized to the patient's poly ( + A)-RNA and used to prime first strand synthesis of cDNA with avian reverse transcriptase (23) . To this DNA/RNA hybrid, we add two 39-mer oligonucleotides which are complementary to sequences on either side of the putative mismatch location. Each oligonucleotide is complementary to 30 nt of sequences containing variations of the nine base repeating unit which are relatively less frequent and each contains a 9 nt restriction enzyme linker sequence. Since the collagen sequences are both very repetitive and very GC rich, regions containing relatively higher AT content will yield more specific matches. In practice, we have obtained good specificity using oligos with 60% GC nucleotides. The oligonucleotides are used to amplify the mismatch-containing region of the DNA/RNA hybrid by the polymerase chain reaction. After the linkers at the ends of the amplified sequences are digested with the appropriate restriction enzymes, the fragments are subcloned into plasmid vectors for sequencing. Isolation and sequencing of the mismatch-containing region can also be accomplished by generating a cDNA library from the patient's fibroblast poly(A+)-mRNA and screening the lambda phage plaques with appropriate probes on either side of the mismatch region (26) . This method is straightforward and reliable but more time consuming.
Subcloning Type I Collagen cDNA to Generate Antisense Riboprobe The cDNAs containing the coding regions for almost the entire COLlAl ( Figure 2A ) and COL1A2 ( Figure 2B ) genes were subcloned into pGEM vectors in a series of overlapping segments. The subclones are described in detail in Table 1 , including the end points of the regions contained in the cloned segments and the plasmids of origin. The subclones were oriented such that transcription using the T7 promoter would generate an antisense riboprobe in run-off transcription. As illustrated in the example shown below, the use of overlapping probes allows both the detection of a mismatch and its localization with respect to the ends of the probes. For those regions of mRNA not covered by overlapping riboprobes, the use of a truncated version of the probe originally detecting the mismatch will usually allow orientation of the mismatch within the probe.
Sensitivity and Specificity of Point Mutation Detection in
RNA/RNA Hybrids with COLlAl RNA The sensitivity and specificity of the hybridization and digestion conditions described above were tested using the RNA from a lethal type II osteogenesis imperfecta (01) proband with a known point mutation in one COLlAl allele. This mutation (Figure 3) consists of a G-U change in the mRNA which results in the substitution of a cysteine for glycine at a 1(1) amino acid residue 988 (1). Hybridization of normal antisense riboprobes to this region of the proband's mRNA would result in a U=C mismatch; this mismatch should be easily detected by RNase A (2). Total RNA from the 01 proband was hybridized with a pair of overlapping riboprobes, pAlEX (Probe 1) and pAlEPC (Probe 2). Both of these probes should allow detection of the point mutation. In addition, comparison of the digestion products of this pair of overlapping riboprobes should allow localization of the mismatch. The antisense probes have a common 3-end, but extend a variable distance toward the 5-end. Cleavage of the mismatch in RNA/RNA hybrids generated with these two probes would yield a common fragment from the 3' end and a unique fragment from each of the 5' ends. In this case, the mismatch is 603 nt from the common end of the probes and 198 nt (Probe 1) and 555 nt (Probe 2) from the unique ends of the probes.
The RNase A cleavage products of hybrids between 01 proband RNA and riboprobes pAlEX and pAlEPC are shown (Fig. 3) . In lanes 1 and 3, there is a common band that migrates slightly slower than the 603 bp band of the <t>X Hae III marker digest. Lanes 1 (Probe 1) and 3 (Probe 2) each have a unique band migrating slightly slower than DN A marker bands of the expected size. Since RNA fragments usually migrate on gel electrophoresis with an apparent size 15-20% larger than DNA fragments of the same size, these cleavage products are in the expected size range. In addition, there is a band co-migrating with the fulllength riboprobe protected by the control RNA. This full-length protection product results from the mRNA produced by the proband's normal allele, as well as the variable portion of mutant allele mRNA not cleaved by RNase A. From the intensity of the cleavage products and the full-length protection product, we would estimate that about 50% of the mutant mRNA is not digested. No spurious cleavage products are seen.
Detection of Mismatches in mRNA of Patients with Osteogenesis Imperfecta
Our series of antisense riboprobes is being used to screen the mRNA of patients with osteogenesis imperfecta and their immediate family members. Seven novel mismatches have been detected in six patients. One such mismatch was localized to a 225 base pair region of al(I) using three overlapping riboprobes. It was isolated by screening a cDNA library synthesized from the patient's fibroblast RNA. Sequencing of the area targeted by the riboprobe analysis demonstrated aG-A point mutation which resulted in a serine for glycine substitution at a 1(1) residue 832 (26) .
We show in Figure 4 the RNase A cleavage products from RNA/RNA hybrid analysis of other OI patients. In each of the cases shown here, overmodification of type I collagen protein had been detected in the patient's dermal fibroblast cultures. The extent of overmodification was also known from electrophoretic analysis of cyanogen bromide peptides of the type I collagen chains. Thus, although the protein data could not distinguish between mutations in a 1(1) and a2(I), it did allow us to target a more limited region of both RNAs for analysis.
Panel A of Figure 4 shows the analysis of the RNA of a 4 year old child with the moderate type IV phenotype of osteogenesis imperfecta (11) and overmodification of all cyanogen bromide peptides of type I collagen. The analysis was performed using the same two antisense riboprobes employed in Figure 3 . This is a screening gel, on which the RNase A digestion products of multiple patients were examined by electrophoresis. The gel is somewhat over-exposed in order to detect mismatches which are poorly digested. These poorly digested mismatches are seen as relatively intense bands which appear more prominent than surrounding background bands. This is a further illustration of the utility of overlapping probes: in this case there is a common fragment of about 390 nt and unique fragments of 490 nt (pAlEX) and 810 nt (pAlEPC). This mismatch was pursued by the scheme outlined in Figure 1 , panel B. It was found to be a A -G point mutation at a 1(1) residue gly 910 (Fig. 5 ) which did not result in a change of amino acid at this location. Unfortunately, the sensitivity and specificity of this strategy does not distinguish rare polymorphisms from mismatches of functional significance. The mRNA of this patient was also probed with pAlPE8, pA2PEl, and pA2HB6 (data not shown). No additional mismatches were detected. Apparently, this patient's functional mutation will not be enzymatically detectable with antisense probes. Panels B and C of Figure 4 show additional screening gels using the mRNA of osteogenesis imperfecta patients and antisense riboprobes. In Panel B, a probe (pA2HB6) complementary to a region coding for the carboxyl terminal end of the a2(I) helical region has allowed the detection of a mismatch (lane 5) in a case of lethal type II osteogenesis imperfecta (11) . (See full molecular description of this case below). No additional mismatches were detected when the RNA was probed with pA2PEl, pAlEPC, pAlEX or pAlPE8 (data not shown).
In Panel C, a mismatch was detected (lane 6) in a case of type in OI (11) using a probe (pAlPE8) complementary to the central portion of the helical region of al(I). The cleavage product migrates just slightly faster than a background band present in all persons screened. However, because the lanes are evenly loaded (as shown by the equal intensity of background bands) and we have seen this product and its small complementary product on multiple 5% and 8% PA gels, respectively, we can be confident that the 'broader' band indicated by the arrow in panel C represents the composite of a background band and the faster migrating cleavage product. Most patients with type III OI do not have demonstrable abnormalities of type I collagen protein. However, this child with classic clinical and radiographic features of type III OI did demonstrate overmodified type I collagen, with the overmodification encompassing about twothirds of the helical region. No additional mismatches were detected with probes pAlEPIO, pA2HB6, pA2AX2 (data not shown).
Cyanogen Bromide Peptides of Type I Collagen of Proband with Type II OI
We have previously shown (Grange, DK, Lewis, MB, and Marini, JC, Am. J. Med. Genet., in press) that the type I collagen synthesized by dermal fibroblasts from the proband consists of two electrophoretic forms: (1) a form which migrates normally on SDS-PAGE as compared with the parental and control collagens, and (2) a form with delayed electrophoretic migration. The form with delayed electrophoretic migration was shown to be due to overmodification of the type I collagen helix. Cultured cells treated with a, a'-dipyridyl, which prevents modification of the helix by inhibiting the hydroxylation required prior to glycosylation, synthesized only type I collagen which co-migrated with parental and control collagens.
The above results indicate the presence of a mutation in either the a 1(1) or a2(I) chain of type I collagen which delays the rate of helix propagation. To obtain an approximate localization of this mutation along the length of helix, we determined the gradient of overmodification in type I collagen by examining the cyanogen bromide peptides of the proband, parental and control cell lines (Fig. 6) . Overmodification is clearly demonstrated in all of the proband's CNBr peptides from the a 1(1) chain and both peptides from the a2(I) chain. This pattern is indicative of a mutation in the carboxyl-terminal quarter of either the al(I) or a2(I) chain.
RNA/RNA Hybrid Analysis of Lethal Type U OI Proband's Type I Collagen mRNA
The mutation in the proband's type I collagen mRNA was localized using the RNA/RNA hybrid system. No mismatches were detected with antisense riboprobes complementary to the region coding for amino acid residues 558 -1185 of a 1 (I). The a2(I) riboprobes covered the region coding for amino acids 700-1341. A mismatch was detected using the 811 nucleotide riboprobe HB6 (Fig. 2B) , complementary to the region coding for amino acids 642-912 of the a2(I) chain. The RNase A digestion pattern of the proband shows a full-length protection fragment and a partial cleavage fragment of approximately 320 nt (Fig. 4B, lane 5) ; the complementary cleavage fragment, approximately 500 nt in size, is not clearly visualized from RNA/RNA hybrids due to co-migration with background Undigested probes and 0X174 Hae III marker fragments are shown to the left. Probe pAlEX was used in lanes 1 to 7; pAlEPC was used in lanes 8 to 15. Lanes 7 and 15 contain normal control RNA; lanes 6 and 14 contain the mRNA with the mismatch detected in Fig 3 as a positive control. Lanes 2 and 10 contain sample from the type IV 01 patient. Mismatches were not detected in the remaining lanes, which contain RNA samples from additional OI patients and family members screened on the same gel. When compared to controls and other patients screened with probes simultaneously, the type IV 01 patient has a common cleavage product from each of the two probes at about 390 nt (arrows), and unique cleavage products of 490 nt (Probe pA 1 EX) and 810 nt (Probe pA 1EPC, not visible in this exposure). Panel B. Mismatch in a2(I) mRNA in patient with type II 01 detected with <*2(I) probe pA2HB6. Lane 7 contains formal control mRNA, lane 5 contains mRNA of the 01 patient, and the remaining lanes contain mRNA of other individuals being screened. A digestion fragment of about 325 nt in length is easily visible in lane 5; the complementary fragment generated from the remainder of the probe is probably masked by migration with a background band. Panel C. Mismatch in the cd(I) mRNA of patient with type III 01 detected with al(I) probe pAlPE8. Lane 1 contains normal control mRNA, lane 6 contains the mRNA of the patient with type III 01, and the remaining lanes contain mRNA of other patients being screened. A digestion fragment of about 750 nt in lane 6 is designated with an arrow and the small complementary fragment of 160 nt generated from the remainder of the probe was detected on an 8% PA-7M urea gel (data not shown).
cleavage fragments. Because we have no overlapping riboprobes in this region of a2(I), it is not possible to localize the mismatch with respect to the ends of the HB6 region. As shown in Figure  7 , the mismatch should be approximately 320 nt from either end of the riboprobe region.
The parental fibroblast mRNAs do not share this mismatch (data not shown). Thus, the mismatch detected here occurs de novo in the proband or as a parental germ-line mutation.
Identification of Subclones Containing Normal and Mutant Allele Inserts
Because our riboprobe system did not have overlapping probes in the HB6 region we used the PCR amplification both to isolate the region of interest and to localize the mismatch with respect to the ends of the riboprobe. The region of the proband's mRNA which was amplified was skewed (Fig. 7) by moving the 5'-end 210 bp upstream and the 3'-end 57 bp upstream. Since the amplified region includes all but 57 nt at the 3' end of HB6 and the mismatch is 320 nt from one end of the probe, the amplified cDNA must include the mismatch in copies of the mutant allele. However, the sizes of the protected fragments from the mutant allele would be expected to differ depending on which end of the HB6 region was closer to the mismatch.
To distinguish subclones containing normal and mutant alleles, the linearized subclones were hybridized with the HB6 antisense riboprobe, digested with RNase A and the products analyzed electrophoretically (Fig. 8) . The subclones containing normal inserts provided full protection for the HB6 probe; two strong digestion bands of 230 nt and 480 nt were seen in the subclones containing mutant inserts. If the mismatch were located closer to the 5'-end of the HB6 region, digestion of DNA/RNA hybrids would be expected to yield the same 320 nt fragment seen on RNA/RNA hybrid analysis. If the mismatch were located closer to the 3'-end of the HB6 region, the smaller digested product would be truncated by about 57 nt. Thus the sizes of the fragments protected by digestion of DNA/RNA hybrids is indicative of a mismatch closer to the 3' end of the HB6 region. The 230 nt fragment from DNA/RNA hybrids and the 320 nt fragment from RNA/RNA hybrids can be used to define the boundaries of a target region likely to contain the mismatches (Figure 7 ). In the case of this proband, the target region was the nucleotides coding for amino acid residues 805-830. Two separate PCR amplifications were subcloned because of the possibility of error in the PCR reactions. From the first amplification, we obtained 5 normal and 4 mutant subclones; from the second amplification, we obtained 4 normal and 5 mutant subclones.
RNA/RNA Mismatch in Proband Represents a Single Nucleotide Change
Sequencing of both alleles for the full HB6 region revealed a single nucleotide change (Fig. 9 ). In the second position of the codon for amino acid 805 there is a G-A mutation which results in the substitution of an aspartic acid for a glycine residue. The immediate region surrounding the mutation was sequenced in the 9 isolates from each PCR amplification, confirming the uniqueness of the mutation.
DISCUSSION
We have developed a strategy for the detection, localization and sequence determination of point mutations in the mRNA coding for the a 1(1) and a2(I) chains of type I collagen. This strategy involves detection and localization of the mutations by RNase A digestion of mismatches in RNA/RNA hybrids between patient mRNA and labelled antisense riboprobes. DNA fragments containing mutations detected by this approach are isolated for sequencing by (1) screening fibroblast cDNA libraries or (2) amplifying the region containing the mutation by the polymerase chain reaction, using DNA/RNA hybrids as the substrate. The difficulties of extending this type of analysis to the mRNAs for the fibrillar collagens include not only the large size of the mRNAs but also the GC-rich and repetitive nature of their sequences (13) . Similar difficulties in analyzing large mRNAs with repetitive sequences pose significant challenges for many eukaryotic genes. To contend with the length of the fibrillar collagen mRNA, the entire cDNAs for the a 1(1) and a2(I) chains of type I collagen were subcloned in overlapping segments into pGEM vectors (16) . Segments were oriented in the vector such that transcription from the T7 promoter would synthesize the antisense riboprobe. This promoter was chosen to maximize the proportion of riboprobe which would be full-length. Nonetheless, the individual riboprobes were limited to approximately 1 kb or less in length because of practical constraints of the gel analysis of the RNase A digestion products. One kilobase is approximately the upper limit of probe size allowing adequate resolution of large cleavage products from fully protected probe. To contend with the extremely repetitive sequences of type I collagen, the specificity was increased by hybridizing the probes to patient rnRNA close to the melting temperature of the hybrids. We used a known point mutation in a 1(1) mRNA (1) and a pair of overlapping riboprobes to demonstrate that the system was sensitive to the predicted mismatch in the RNA/RNA hybrid and that hybridization was specific for the target sequences. We also demonstrated that overlapping riboprobes could confirm the existence of the mismatch and reveal its location relative to one end of the riboprobes. Despite these adaptations of RNA/RNA hybrid analysis to the large and repetitive mRNAs of type I collagen, the system still has limitations. The background of radioactive bands on the gels may be relatively high, especially when one is looking for a poorly cleaved mismatch. In these cases, mismatches are best detected as relatively more intense bands which stand out against the background provided by screening many individuals with the same riboprobe on the same gel. Furthermore, a sizable proportion of mismatches may be missed altogether because of RNase A preference for cleaving after pyrimidines (27) . Fortunately, false positive cleavages appear to occur infrequently. Mixing RNases A and Tl does not appear to alter the number of cleavages detected on the sense strand. Generation of cDNA from patient mRNA and probing of both strands with sense and antisense probes should allow detection of all mismatches.
The sensitivity of this methodology for single base pair mismatches raises a different question: what is the functional significance of a particular point mutation for the disease? Rigorous proof of functional significance would require transgenic experiments or linkage studies that are not practical for investigating isolated cases. Cautious conclusions can often be drawn by combining data from nucleic acid and protein analyses.
In this report, we have delineated a new point mutation in one allele of a2(I) collagen which is associated with a case of lethal type II 01. Sequencing revealed that the mutation consisted of a G-A change in the second position of the codon for glycine residue 805 and resulted in the substitution of an aspartic acid at this position. The mutation was located within the target region of amino acid residues 805 -830, as defined by the combination of the sizes of RNA/RNA and DNA/RNA digestion products. The location of the mutation in the a2(I) chain is consistent with the predictions of hybrid analysis. Its occurrence in a glycine residue of the repeating Gly-X-Y unit of fibrillar collagens is consistent with all other point mutations described in both types II and IV OI, the lethal and moderately severe forms, respectively. Difficulty in accommodating the bulky, charged side chain of aspartic acid into the internal position normally occupied by glycine in the helix would result in delay of helix propagation and consequent overmodification of the portion of the trimer amino-terminal to the mutation. The proband's protein data is consistent with these expectations. We have previously demonstrated (Grange, DK, Lewis, MB, Marini, JC; Am. J. Med. Genet., in press) that the type I collagen of the proband consists of both the normal form, as present in normal control and parental lines, and an overmodified form. The collagen helices of the proband have a lower thermal stability than those of a control line and are susceptible to trypsin digestion at 1 °C lower temperature. When the CNBr peptides of the a chains of the proband are examined electrophoretically (Fig. 6 ), all CNBr peptides are shown to contain overmodified forms. Thus, the location of the mutation is consistent with protein and RNA data from the proband and the aspartic acid substitution is of the type which would be expected to generate the proband's biochemical abnormalities.
This case confirms that lethal osteogenesis imperfecta is associated with mutations in both chains of type I collagen. Over a dozen substitutions for glycine residues have been found in the a 1(1) chain; this is the third case of lethal OI associated with a substitution for glycine in the a2(I) chain (28, 29) . The three amino acid substitutions in a2(I) associated with lethal OI are clustered within about 100 residues of each other, from gly 805 to gly 907. Clearly, the amplification effect of multimeric structure on the proportion of helices containing mutant a 1(1) chains is not an essential part of the lethal phenotype.
Delineation of further mutations in the a2(T) chain in both types II and IV OI is required to define the pathologic map of the chain. Instead of a separation of clinical types based on the location of a mutation in the a 1(1) or a2(I) chain, we may find a mosaic of interspersed clusters of mutations associated with either types II or IV OI. Such a mosaic of mutation/pathology clusters could be the result of a regular distribution of crucial points of interaction of the type I collagen helix with other components of the skeletal extracellular matrix, such as osteonection, fibronectin, or bone sialoproteins. Thus, mutations in certain crucial regions along the type I collagen helix, in either the al(T) or the a2(I) chain, might have serious pathologic consequences; mutations in other less important regions would have a mild clinical presentation. In a matrix mosaic model, the pathologic effect of individual point mutations would be expressed within the context of the larger topology of collagen/matrix component interactions.
The series of antisense riboprobes described here is directly useful for the detection and localization of mutations in the type I collagen mRNA of patients with osteogenesis imperfecta. In some cases, this information will confirm and refine the protein data. In those cases in which no abnormality has been detected at the protein level, including most cases of the severe progressive deforming type HI OI, such a system will facilitate our investigation of whether mutations are indeed present in type I collagen. In addition, these probes can be used to study other heritable connective tissue disroders. They may also have a role in investigations of familial osteoporosis. A similar strategy may be applied to the mRNA for type IB collagen in patients with Ehlers-Danlos syndrome. The general strategy has wide applicability for the analysis of mutations in other large and repetitive genes.
